Wockhardt launches generic midazolam injections in the US
This article was originally published in Scrip
Wockhardt has launched preservative-free midazolam injections 1mg/ml and 5mg/ml in the US. The product is a generic version of Roche's Versed for acute insomnia and anxiety and represents Wockhardt's fourth injection ANDA approval in the past two months and the twelfth sterile product to be approved in the US. Wockhardt now has FDA approval for both preservative-free injections containing midazolam, and midazolam injections containing preservatives. The injections are manufactured at Wockhardt's US FDA-certified formulation plant in Waluj. The US market for midazolam injections is estimated at $56 million.
You may also be interested in...
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
The head of global vaccine and plasma segments, bioprocessing, at German multinational Merck discusses key aspects around evolving vaccine manufacturing to improve the efficiency and speed of response during a pandemic. Pre-existing manufacturing platforms, the executive says, could compress process development work and fast-track scale-up.
Glenmark and Sun Pharma introduce nintedanib generics in India at a fraction of the innovator product’s price, vying for a share of the IPF market where pirfenidone currently holds sway.